Prescription medicine
Gramicidin and neomycin and polymyxin b
Gramicidin and neomycin and polymyxin b is a prescription medicine. FDA's NDC Directory lists it from 2 generic labelers, and pharmacies paid $4.59 per mL (Neomyc-polym-gramicid eye drop) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the gramicidin and neomycin and polymyxin b FDA label on DailyMed (effective September 18, 2024, Bausch & Lomb Incorporated); every gramicidin and neomycin and polymyxin b label on DailyMed.
Highlights of the record
FDA label of September 18, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNeomycin and polymyxin B sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria.
Forms and strengths
- 1.75 mg/ml / 0.025 mg/ml
Solution/ drops.
On the market
- Generic approvals
- 3 first July 3, 1968; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 2 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.59 per mL Neomyc-polym-gramicid eye drop
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 8 through July 30, 2026
What is gramicidin and neomycin and polymyxin b used for?
From the label: indications and usageNeomycin and polymyxin B sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
FDA pharmacologic class: Aminoglycoside Antibacterial and Polymyxin-class Antibacterial.
Source: FDA drug label (NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN), Bausch & Lomb Incorporated, effective September 18, 2024 (SPL set e6f8d2f6-adff-4ae1-982c-45562f0a8e28), via openFDA; the full label on DailyMed
Is there a generic for gramicidin and neomycin and polymyxin b?
The FDA approved the first generic gramicidin and neomycin and polymyxin b on July 3, 1968. 3 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists gramicidin and neomycin and polymyxin b from 2 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for gramicidin and neomycin and polymyxin b?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.59 per mL (Neomyc-polym-gramicid eye drop), up 3% from $4.44 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Neomyc-polym-gramicid eye drop (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Neomyc-polym-gramicid eye drop | Generic | $4.59 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for gramicidin and neomycin and polymyxin b?
The FDA Adverse Event Reporting System holds 8 reports that list gramicidin and neomycin and polymyxin b among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other aminoglycoside antibacterials
- the pharmacologic class, with prices and generics
- Gramicidin and neomycin and polymyxin b side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other